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we used the Medicare LDS 5% sample including years 2011-2013. MG patients 
were identified using the ICD-9 code 358.0 and were required to have at least two 
diagnoses. MG patients were indexed in the year 2012 and followed for a period of 
one year to assess costs and healthcare utilization. Results: We identified 2,047 
MG, 1,050 male and 997 female, patients in the Medicare sample giving a prevalence 
of 77/100,000. Male and female prevalences were 68 and 87/100,000, respectively. On 
average, male patient were older than females by 2.66 years (p= 0.01), had higher 
CCI scores (2.59 males, 2.21 for females, p= 0.01) and were less likely to be receiving 
Medicare disability benefits (16.67% and 25.68%, p= 0.01). Female MG patients were 
more frequently in the highest category for inpatients stays (12.94%, 9.14%, p= 0.03) 
and ER visits (36.81%, 31.81%, p= 0.01). ConClusions: Among Medicare beneficiar-
ies MG is more prevalent than in the US population. Large differences seen in the 
literature between male and female patients were not seen, most likely due to the 
specific nature of the Medicare beneficiary population. Female MG patients had 
higher rates of healthcare utilization, but cost differences were negligible.
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objeCtives: To determine the incidence and prevalence of patients diagnosed 
with MW (with or without other diagnoses of cancer) and to determine rate and 
type of chemotherapy and care settings using sickness data. Methods: Data 
from 1,771,217 beneficiaries in 2012 were analysed. A patient was incident for WM 
if no diagnosis was coded in 2010. WM patients were identified by ICD-10 C88.0, 
oncological co-diagnoses by ICD-10, chemotherapy by Anatomical Therapeutic 
Chemical (ATC) Code L01*, pharmacy number (PZN) 9999092 and/or operating and 
procedure code (OPS) 8-54*. Results: 108 patients with a diagnosis C88.0 could 
be identified (prevalence 0.0060%). 22 (20.4%) of them had their first diagnosis 
in 2012 (incident). Overall gender ratio was 56.5% male and 43.5% female. The 
highest share of patients was found in the age class 70-79 (41.7%). Additional 
oncological diagnoses were found in 67 (62.0%) patients diagnosed with WM. Top 
3 reported oncological disorders were: 61 (41.5%) had neoplasms with unknown 
behaviour (D37-48), 40 (27.2%) had a melanoma (C43-44) and 10 (6.8%) had malig-
nant neoplasms of male genital organs (C60-63). The outpatient diagnosis rate for 
WM was 84.3%, inpatient rate 3.7% and in- and outpatient rate 11.1%. 10 of the 
108 patients (9.3%) started chemotherapy in 2012 (30.0% out- and inpatient and 
70.0% outpatient). 3 of the incident patients (n= 22) started chemotherapy (13.6%) 
and 7 of the prevalent (n= 86, 8.1%). 6 patients received first-line (1 monotherapy) 
and 4 second-line treatment. Prescribed compounds were identified by ATC (out-
patient only): 75.9% rituximab, 48.3% bendamustine, 20.7% chlorambucil, 17.2% 
cyclophosphamide, 6.9% fludarabine and 6.9% vincristine (data suggesting com-
binations). ConClusions: The yearly chemotherapy rate was 9.3%. The major-
ity of the patients received no chemotherapy (n= 98, 90.7%). Most of the patients 
were diagnosed and treated in the outpatient sector. Oncological disorders were 
relatively high (62.0%).
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objeCtives: Obesity is a major risk factor for the development of multiple acute 
and chronic illnesses such as diabetes, cardiovascular diseases, stroke, and cancer. 
In order to improve targeting of resources for weight loss intervention, this study 
identified subgroups in a generalizable population who currently have the lowest 
rates of weight loss. Methods: This is a population-based retrospective observa-
tional study that assessed measured weight loss in 2014 among adolescents (13-17 
years old) and adults (25 years and older) members of Clalit Health Services (Clalit), 
the largest health maintenance organization in Israel, who were documented as 
obese (95 percentile and above for adolescents and BMI≥ 30 for adults) between 2010 
and 2014. Results: There are more than 14,000 adolescents and 420,000 adults, 
9.8% and 23.6% of the population in 2014 respectively, who were documented as 
obese between 2010 and 2014. Of those, in 2014, 13.2% adolescents and 13.5% adults 
no longer met the criteria for obesity. This change in BMI differed by age for both 
boys and girls, from 2.2% for those aged 13 to 17.4% for those aged 17, and from 3.8% 
for those aged 13 to 20.9% for those aged 17, respectively. Among adults, transition 
from obesity was the lowest among women in the 45-54 year age group (10.5%). 
Those with the lowest socioeconomic status also had lower rates compared to the 
highest socioeconomic status (11.4% vs. 15.4%, respectively for adolescents and 
11.9% vs. 16.7% for adults). ConClusions: As of 2014, less than 20% of the obese 
population has lost sufficient weight to not be considered obese. Members from 
low socioeconomic status and midlife-age women have the lowest reducing weight 
rates. Therefore, healthcare providers and weight loss interventions should consider 
focus on those populations.
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objeCtives: Anemia is one of the most commonly occurring hematological disor-
der in Indian women. The estimation of anemia prevalence in Indian women helps 
the health policy makers. The objective of the present study is to prevalence, severity 
of anemia among women in India. Methods: A systematic literature search was 
performed in PubMed and Elsevier ScienceDirect, Cochrane library databases and 
Google scholar (from 1990 to April 2015). All the eligible studies with full text and 
satisfy the inclusion criteria were included for study. Study consist of women in age 
ence improvements into changes in Validated Haemophilia Regimen Treatment 
Adherence Scale for Prophylaxis (VERITAS-Pro) scores, allowing us to illustrate 
specific aspects of adherence improvements with extended-half-life products 
potentially associated with significant reductions in ABRs. Results: Extrapolated 
ABRs for rFVIII and rFIX at 76% adherence were 12.7 and 7.4, respectively. The 
extrapolated rFVIIIFc ABR was significantly lower vs. conventional rFVIII for adher-
ence levels > 82% (Δ ABR > 3.0, P< 0.05). The extrapolated rFIXFc ABR was signifi-
cantly lower vs. conventional rFIX for adherence levels > 85% (Δ ABR > 2.0, P< 0.05). 
Depending upon initial adherence levels, our estimates suggest these adherence 
improvements are comparable to improvements in VERITAS-Pro total scale of 5-22 
points. ConClusions: Simulations using a model to understand the relation-
ship between adherence and ABR suggest improved adherence to prophylaxis 
associated with rFVIIIFc and rFIXFc may lead to significant reductions in bleeding 
rates.
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coSt eFFectiveneSS oF multidiSciPlinarY Pain management ServiceS 
For chronic back Pain: SYStematic revieW
Almazrou S1, Elliott R1, Knaggs R2
1university of Nottingham, Nottingham, UK, 2University of Nottingham, Nottingham, UK
objeCtives: This systematic review aims to summarise and critically appraise 
the current evidence for the cost effectiveness of multidisciplinary pain man-
agement services in managing chronic back pain. Methods: Electronic search 
was conducted in three clinical databases, which include: MEDLINE, EMBASE and 
PsycINFO (using Ovid interface) from their inception to March 2015.Other data-
bases such NHS Economic Evaluation Database (NHS EED) and Health Technology 
Assessment Database (HTA) in the Centre for Reviews and Dissemination (CRD), 
were also explored to retrieve economic evaluation studies. The quality of ran-
domised clinical trials was assessed by Cochrane Back Review Group (CBRG) risk 
assessment tool. Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist was used to assess the methodological quality of reporting eco-
nomic studies. Results: Five studies fulfilled our eligibility criteria. All of them 
were economic evaluations alongside randomised clinical trials. Two studies were 
from Norway, two from the Netherlands and one from the United Kingdom. These 
studies were published between 2002-2014. Two out of Five studies were consid-
ered having “low risk of bias). Three cost effectiveness studies showed that multi-
disciplinary pain management services were cost effective compared with usual 
care and surgery. The remaining studies showed that these services were not cost 
effective. ConClusions: Current evidence is inadequate to determine the cost 
effectiveness of multidisciplinary pain management services due to the variability 
of the interventions, comparators and outcomes.
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objeCtives: In the past decade, there was a marked increase in the number of 
tramadol-related deaths in the UK, and these fatalities occurred in persistent trama-
dol users prescribed antidepressants concomitantly. However, the prevalence of 
such combinations has not been explored in the UK. This study took a prescription 
sequence symmetry analysis approach to explore the prevalence of antidepres-
sants prescription before and after the initiation of tramadol. Methods: This 
retrospective cohort study used the Clinical Practice Research Datalink. Patients 
who were prescribed tramadol from 2000 to 2011 were identified and prescriptions 
of tramadol and antidepressants were followed 9 years before and after the date 
of the first tramadol prescription. Patients who were issued at least one tramadol 
prescription consecutively in each follow-up patient year were defined as persistent 
users. The proportions of tramadol users combined with antidepressants before 
and after tramadol initiation were compared by Chi square test and stratified by 
non-persistent and persistent tramadol users. Results: Of the 526,624 included 
tramadol users, 22,003 (4.2%) were persistent users. The proportion of co-prescribing 
antidepressants in tramadol users significantly increased from 44.1% to 49.3% after 
the initiation of tramadol (P< 0.001). Of those co-prescribed with antidepressants, 
the proportions of co-prescribing tricyclic antidepressants and selective serotonin 
reuptake inhibitors (SSRIs) were higher than other antidepressants. After tramadol 
initiation, proportions of co-prescribing SSRIs changed +0.2% and -1% in persis-
tent and non-persistent groups, respectively. Comparing to persistent group, the 
prevalence of co-prescribing SSRIs was higher in non-persistent groups (56.2% vs. 
49.9%) after tramadol initiation. ConClusions: The increased prevalence of co-
prescription of antidepressants after initiation of tramadol shows that adverse 
drug-drug interactions might be underestimated by prescribers. Further studies 
are needed to evaluate the impact of such co-prescription on clinical outcomes 
and resource utilisation.
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objeCtives: Myasthenia Gravis (MG) is a rare neuromuscular disease affecting an 
individual’s voluntary muscular control. It is estimated that the US prevalence of 
MG is 20/100,000, however there is little information specifically focused on older 
adults. Evidence suggests that MG impacts men and women differently with women 
having an earlier onset of disease than men. We calculated the prevalence of MG 
among Medicare beneficiaries and assessed differences in patient characteristics 
and costs between male and female patients. Methods: To complete our study 
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rare disease, is a target for enzyme replacement therapies, yet UCD epidemiology 
data are scarce. The objective of this study is to estimate the prevalence of UCD 
in the 0–17 year-old population in five major European markets (EU5) (France, 
Germany, Italy, Spain, UK). Methods: We designed an incidence-survival model 
utilizing birth incidence, annual life-expectancy and country-specific newborn 
data. Birth incidence estimates for UCD were obtained from the Urea Cycle 
Disorders Consortium (UCDC). We conducted a literature review to determine 
the annual life expectancy of UCD. Finally, we reviewed available EU5 newborn 
census data to obtain the number of newborns in each country from 2001 to 2012. 
We extrapolated the trend from 2001-2012 to forecast the number of newborns 
through 2024. These data were entered into the incidence-survival model to calcu-
late the prevalence of UCD from 2015-2024. Results: We estimated a prevalence 
of 1.71 per 100,000 population in the 0–17 year age groups resulting in 1,027 and 
1,033 UCD cases in the EU5 in 2015 and 2024, respectively. The prevalence was 1.89 
per 100,000 in the 0-4 year-old age group, 1.63 per 100,000 in the 10-14 year-old 
age group, and 1.57 per 100,000 in 15-17 year-old age group. ConClusions: To 
our knowledge, this study provides the first prevalence estimate of UCD in the 
EU5 markets. With 1,027 estimated cases in 2015, it is expected that UCD treat-
ments will be expensive given the small size of the patient population. Further, 
these estimates can be used to approximate the total cost burden of UCD and the 
resulting cost-effectiveness of UCD treatments.
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objeCtives: To explore the relationships between characteristics of patients 
with multiple myeloma (MM) and clinical and economic outcomes to identify 
which patient subgroups contribute the greatest clinical and economic bur-
dens. Methods: Literature was systematically searched for relevant articles pub-
lished between 2004 and 2014. A database of patient characteristics, outcomes and 
subgroup-specific information was created and analysed to explore relationships 
between patient characteristics and outcomes. The coefficient of determination 
(R2) was calculated to examine the strength of these relationships to help to formu-
late hypotheses for further research. Results: Objective response rate (ORR) and 
overall survival (OS) were the most commonly reported outcomes, while economic 
outcomes data were limited. Although patient characteristics varied across studies, 
several trends were observed. There was a weak correlation between increasing 
age and higher OS (R2 = 0.0185) and ORR (R2 = 0.0305). OS decreased (R2 = 0.2428) 
as the proportion of patients with International Staging System (ISS) stage III MM 
increased; however, only five studies reported OS by ISS subgroup. ORR decreased (R2 
= 0.2843) as the proportions of patients with no prior stem cell transplantation (SCT) 
increased and a small decrease in OS was observed (R2 = 0.0280), but SCT eligibility 
did not demonstrate consistent outcome trends. A trend towards increased OS was 
seen with previous treatment with bortezomib (R2 = 0.3057) or thalidomide (R2 = 
0.2612). In contrast, previous treatment with these agents was associated with a 
worse ORR (R2 = 0.1926 and R2 = 0.2617, respectively). ConClusions: SCT status 
and prior therapies appear to affect outcomes, and a trend was seen between ISS 
stage III MM and poor prognosis. This exploratory approach has generated hypoth-
eses for further research into how patient characteristics influence resource use 
and cost. A better understanding of how patient factors impact on outcomes may 
facilitate better targeting of treatment.
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objeCtives: The objective of the study was to provide a comprehensive overview 
of existing risk prediction models of mortality, complications, and remission of 
diabetes after bariatric surgery. Methods: A systematic literature review was 
performed in Medline, Medline-In-Process, EMBASE, and the Cochrane Central 
Register of Controlled Trials (CENTRAL) databases in April 2015. All English lan-
guage full-text published derivation and validation studies for risk prediction mod-
els focusing on safety and diabetes outcomes of bariatric surgery were included. 
Two reviewers independently performed screening of the studies. Data extraction 
included population, outcomes, variables, intervention, model discrimination, 
and calibration. Results: Of the 2331 studies retrieved from the search, only 
25 studies met the inclusion criteria. Of these, 20 presented development of risk 
prediction models/scores, and five reported validation of existing models. Six 
models were each developed to predict mortality (in-hospital, at 30 days, 90 days, 
and ten years), complications (during perioperative, at 30 days, and 90 days), and 
remission of type 2 diabetes (post-operative, and at one year); and two models 
developed to predict both mortality and complications (at 30 days). Internal valida-
tion using bootstrap resampling or tenfold validation was reported for six models, 
while five models had external validation using independent patient cohorts: 
ABCD score (remission of type 2 diabetes at one year), DiaRem Score (remission 
of type 2 diabetes at one year), Gupta’s model (remission of type 2 diabetes at one 
year), Maciejewski’s model (complication at 90 days), and OS-MRS (mortality at 
90 days). Models included on average 6.9±3.5 variables (range 2-13). Calibration 
and discrimination statistics were not reported for all models. ConClusions: 
There are a variety of risk prediction models for safety and diabetes outcomes of 
bariatric surgery available. However, only few models have undergone external 
group 15-45 were included for study. According to WHO, anemia in non-pregnant 
women age 15-45 years were classified as mild (110-119g/l), moderate (80-109g/l) 
and severe (less than 80g/l) on the basis of hemoglobin concentration. Results: 
A total of six studies satisfy the inclusion criteria were included for study purpose. 
It includes a total of 4684 anemic women ranging from 26 to 3835 from different 
rural and urban parts of India. The overall prevalence of anemia from the pooled 
estimates was 53.2% (95% CI, 41.1-64.9). Prevalence in rural and urban parts of India 
was found to be 55.2% (95% CI, 12.6-41.5) and 49.5% (95% CI 32.9-66.3), respectively. 
Among all the anemic patients cases, mild 31.6% (95% CI, 30.2-33.0) contributes 
maximum number of patients followed by moderate 19.3% (95% CI, 18.1-20.6), and 
severe 2.2% (95% CI, 1.8-2.7). ConClusions: Anemia is highly prevalent in Indian 
women. Nearly equal prevalence was reported from both rural and urban women 
population. Mild form of anemia was found to be more prevalent.
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objeCtives: Anemia and iron deficiency are common during pregnancy and 
expose mothers to several risks such lower resistance to infections or reduced 
tolerance to significant blood loss and to surgical interventions during labor. 
Regarding the foetus, presumed risks include unfavourable obstetric outcomes, 
notably, premature birth, low birth weight and fetal death. The present study aims 
at exploring the prevalence of iron deficiency and anemia among pregnant women 
in France and at evaluating the management of these conditions. Methods: A 
prospective observational study was conducted in France between March 2013 and 
June 2014. Randomly selected investigators (gynecologists, obstetricians, midwives 
registered in the CEGEDIM® database) were asked to include consecutive pregnant 
women presenting for a consultation. At study inclusion, a two-section question-
naire was completed by both the patient (self-assessment) and the investigator. 
Data collected consisted in age, gestation week, laboratory values (e.g. Hb, fer-
ritin), type and reason for the prescription of medication and lifestyle or dietary 
advice given/received. Results: 1506 patients were enrolled by 95 centres and 
data were analyzed for 1478 women. Investigators estimated that almost 60% of 
women were at moderate or significant risk of iron deficiency. Ferritin levels was 
< 15 µg/L in 30.9% of individuals (18.7%, 31.7% and 51.2% at the 1st, 2nd and 3rd 
trimesters, respectively) and the overall prevalence of anemia was 15.8%. However, 
the proportions of these conditions increased with longer pregnancy duration. 
Medication for iron deficiency was prescribed to 57.3% of patients. 98.5% of anae-
mic women and respectively 97.8% and 73.6% of women at significant or moderate 
risk of iron deficiency were prescribed medications (most iron-based). Among 
women receiving treatment, 43.1% had clinical signs of anemia and 39.3% received 
systematic prevention iron . ConClusions: In French clinical practice, the iron 
deficiency isk and anemia prevalence during pregnancy align with medical 
expectations. These conditions are managed according to national/international 
recommendations.
PSY21
Prevalence oF tranSthYretin Familial amYloid PolYneuroPathY in 
Portugal
Inês M1, Coelho T2, Conceição I3, Duarte-Ramos F4, Carvalho M3, Costa J5
1Instituto de Medicina Molecular, Lisboa, Portugal, 2Unidade Clinica de Paramiloidose, Hospital de 
Santo Antonio, Porto, Portugal, 3Centro Hospitalar de Lisboa Norte, Lisbon, Portugal, 4Faculty of 
Pharmacy Lisbon University, Lisbon, Portugal, 5Institute of Molecular Medicine, Lisbon, Portugal
objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. Although 
a rare disease, Portugal has one of the largest TTR-FAP foci in the world but recent 
Portuguese epidemiological data is lacking. The purpose of this study was to esti-
mate TTR-FAP prevalence in Portugal. Methods: TTR-FAP patient’s medicines utili-
zation is fully funded by National Health System in Portugal since 2001. Since March 
2013 Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. TTR-
FAP anonymized patient’s data was requested to Administração Central do Sistema 
Saúde (ACSS). The most frequent municipality used for medicines dispensing by 
each patient was identified and used as a proxy for residence. Portuguese popula-
tion by municipality was obtained from Instituto Nacional Estatística. Prevalence 
was reported at country level and by municipality as number of cases per 100 000 
inhabitants. Results: Over the year 2014, two thousand and thirteen (2 013) TTR-
FAP anonymized patients were registered in ACSS database. A prevalence of 20 
per100 000 inhabitants was estimated for TTR-FAP in mainland Portugal. The dis-
ease is spread across 160 of the 278 Portuguese mainland Portuguese municipali-
ties. The municipalities with higher TTR-FAP prevalence are: Póvoa de Varzim (198), 
Pampilhosa da Serra (191), Seia (170), Esposende (138), Vila do Conde (136), Figueira 
da Foz (134), Boticas (111) and Barcelos (110). ConClusions: We can conclude 
that Portuguese ACSS electronic prescription database is useful, relevant and an 
accessible strategy to estimate the prevalence of some diseases in Portugal. We can 
estimate that TTR-FAP disease has a prevalence of 20 per 100 000 inhabitants and 
it is disseminated across the country being Póvoa de Varzim historically and still 
the most impacted municipality with 198 cases per 100 000 inhabitants, nearly ten 
times higher than country prevalence.
PSY22
calculating the Prevalence oF urea cYcle diSorderS in the eu5 
uSing an incidence–Survival model
Megeed G
Deerfield Institute, New York, NY, USA
objeCtives: Gene therapies for rare diseases have ignited industry-wide debates 
concerning patient access, pricing and efficacy. Urea cycle disorder (UCD), a genetic 
